<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="RevAutoimmun RevAutoimmunity Reviews1568-99721873-0183Elsevier B.V. S1568-9972(20)30078-1 doi: 10.1016/j.autrev.2020.102523102523 : Article COVID-19" exact="infection" post="and rheumatoid arthritis: Faraway, so close! FavalliEnnio Giulioenniofavalli@me.comaâ�ŽIngegnoliFrancescaabDe LuciaOrazioaCincinelliGilbertobCimazRolandobcCaporaliRobertoab[a],"/>
 <result pre="even though several compounds are now under investigation for the" exact="treatment" post="of this life-threatening disease. COVID-19 pandemic is certainly conditioning"/>
 <result pre="of this life-threatening disease. COVID-19 pandemic is certainly conditioning the" exact="treatment" post="strategy of a complex disorder as rheumatoid arthritis (RA),"/>
 <result pre="drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2" exact="infection" post="is leading to consider some anti-rheumatic drugs as potential"/>
 <result pre="infection is leading to consider some anti-rheumatic drugs as potential" exact="treatment" post="options for the management of COVID-19. In this review"/>
 <result pre="other hand, the growing knowledge about the pathogenesis of SARS-CoV-2" exact="infection" post="is leading to the introduction of drugs commonly used"/>
 <result pre="leading to the introduction of drugs commonly used for the" exact="treatment" post="of rheumatoid arthritis (RA) even for the management of"/>
 <result pre="been permanently included, alongside antiviral drugs, in protocols for the" exact="treatment" post="of COVID-19 pneumonia [10]. In addition, the use of"/>
 <result pre="consequent ARDS occurring in the most aggressive patterns of SARS-CoV" exact="infection" post="[11]. Therefore, waiting for observational data on the incidence"/>
 <result pre="this context of health emergency. 2 The pathophysiology of COVID-19" exact="infection" post="Coronaviruses are the largest viruses with a positive-sense single-stranded-RNA"/>
 <result pre="AT2 alveolar epithelial cells, which are particularly prone to viral" exact="infection" post="[13]. SARS-CoV-2 infection leads to the downregulation of ACE2"/>
 <result pre="cells, which are particularly prone to viral infection [13]. SARS-CoV-2" exact="infection" post="leads to the downregulation of ACE2 expression, thus resulting"/>
 <result pre="blockers may have an increase of both the risk of" exact="infection" post="and the severity of COVID-19 [15]. As only scarce"/>
 <result pre="of the genetic predisposition for an increased risk of SARS-CoV-2" exact="infection" post="due to ACE2 polymorphisms that have been linked to"/>
 <result pre="needs regarding COVID-19 infection. 3 Is the risk of viral" exact="infection" post="increased in RA patients? The relationship between RA and"/>
 <result pre="aberrant autoimmune reaction produced by the host response to the" exact="infection" post="is well known [23,24]. Few studies have investigated a"/>
 <result pre="other hand, RA patients carry a documented increased risk of" exact="infection" post="compared with the general population. A population-based study by"/>
 <result pre="polyarthritis reported a 2- to 4-fold increased risk of hospitalized" exact="infection" post="compared to healthy population [31]. This trend is primarily"/>
 <result pre="renewed by the latest update of EULAR recommendations for RA" exact="treatment" post="[36]. Even though CS efficacy in rapidly suppressing inflammation"/>
 <result pre="high risk of developing comorbidities further increasing the risk of" exact="infection" post="[27,38]. Although RCTs conducted in the past with CS"/>
 <result pre="pÂ =Â .0002), increased rate of secondary bacterial or fungal" exact="infection" post="(RR 2Â·0, 95% CI 1Â·0â€&quot;3Â·8; pÂ =Â .04), and"/>
 <result pre="574 patients, concluded that insufficient evidence exists to recommend CS" exact="treatment" post="[48]. Overall, no clear reason exists to expect that"/>
 <result pre="no clear reason exists to expect that patients with COVID-19" exact="infection" post="will benefit from CS, and they might be more"/>
 <result pre="current interim guidance from WHO on clinical management of COVID-19" exact="infection" post="advises against the use of CS unless indicated for"/>
 <result pre="increase the susceptibility and worsen the clinical course of COVID-19" exact="infection" post="in treated patients [15]. In addition, the use of"/>
 <result pre="the fever rise during COVID-19, resulting in a delay in" exact="diagnosis" post="and proper management of the infection. 4.2 csDMARDs The"/>
 <result pre="without corticosteroids was associated with a small decrease in mild" exact="infection" post="risk (adjusted rate ratio [RR] 0.90, 95% confidence interval"/>
 <result pre="[95% CI] 0.88â€&quot;0.93) and was not associated with increased serious" exact="infection" post="risk (adjusted RR 0.92, 95% CI 0.85â€&quot;1.0). Similarly, another"/>
 <result pre="a claim database demonstrated a slightly reduced risk of hospitalized" exact="infection" post="for methotrexate (adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and"/>
 <result pre="the literature confirmed the lack of an increased risk of" exact="infection" post="in patients receiving MTX (RR: 1.14; 95% CI, 0.98â€&quot;1.34)"/>
 <result pre="these reports provided no data on the risk of stratified" exact="infection" post="by pathogen. 4.3 bDMARDs The risk of infection observed"/>
 <result pre="of stratified infection by pathogen. 4.3 bDMARDs The risk of" exact="infection" post="observed in RA patients treated with bDMARDs is generally"/>
 <result pre="1.40; 2.88) [69], and the risk of serious hospitalized HZV" exact="infection" post="is 2-fold higher versus all bDMARDs [70]. Older age,"/>
 <result pre="anti-rheumatic drugs? Currently, vaccines and approved targeted therapeutics for the" exact="treatment" post="of the new SARS-CoV-2 infection are still lacking and"/>
 <result pre="approved targeted therapeutics for the treatment of the new SARS-CoV-2" exact="infection" post="are still lacking and the management of COVID-19 is"/>
 <result pre="a multitude of compounds are now under investigation for the" exact="treatment" post="of this emerging disease [75]. The need to urgently"/>
 <result pre="effective approach to manage COVID-19 led to the strategy of" exact="testing" post="the efficacy of the existing antiviral drugs commonly used"/>
 <result pre="analogue currently under development for the management of Ebola virus" exact="infection" post="[78], has been recently recognized as a promising antiviral"/>
 <result pre="good preliminary in vitro results in the control of SARS-CoV-2" exact="infection" post="[80]. Consequently, lopinavir-ritonavir and remdesevir are currently the only"/>
 <result pre="at the moment these can only be considered as potential" exact="treatment" post="options for the future, but they are obviously not"/>
 <result pre="of specific anti-viral products, many drugs commonly used in the" exact="treatment" post="of RA have been proposed as possible therapies for"/>
 <result pre="consequence of the increased knowledge about the pathophysiology of the" exact="infection" post="(Table 1 ). Table 1 Potential role of anti-rheumatic"/>
 <result pre="with viral penetration into the cell Slight increase in viral" exact="infection" post="risk NSAIDs â€&quot; Facilitation of viral penetration by overexpression"/>
 <result pre="Facilitation of viral penetration by overexpression of ACE2 Delay in" exact="diagnosis" post="due to fever masking Corticosteroids â€&quot; Increased risk of"/>
 <result pre="due to fever masking Corticosteroids â€&quot; Increased risk of viral" exact="infection" post="Increased mortality and risk of secondary bacterial or fungal"/>
 <result pre="infection Increased mortality and risk of secondary bacterial or fungal" exact="infection" post="ACE2Â =Â angiotensin converting enzyme 2, ARDSÂ =Â acute"/>
 <result pre="currently ongoing in China, where it is tested for the" exact="treatment" post="of COVID-19 under various combination protocols with the anti-viral"/>
 <result pre="patients have demonstrated that chloroquine is superior to the control" exact="treatment" post="in improving lung imaging findings, inhibiting the exacerbation of"/>
 <result pre="to be the best option for the management of SARS-CoV-2" exact="infection" post="[93]. 5.2 IL-6 and IL-1 blockers As already described,"/>
 <result pre="already described, ARDS occurring in most severe case of COVID-19" exact="infection" post="is mainly produced by the massive release of pro-inflammatory"/>
 <result pre="hyperinflammatory condition, suggesting the potential use of their blockers as" exact="treatment" post="option for SARS-CoV2 related interstitial pneumonia. Data from a"/>
 <result pre="The identification of a unique definition of CRS during COVID-19" exact="infection" post="is crucial to better customize the management of critical"/>
 <result pre="be additional parameters potentially useful to discriminate patients requiring immunosuppressive" exact="treatment" post="[22]. 5.3 TNF inhibitors As previously described, SARS-CoV infection"/>
 <result pre="immunosuppressive treatment [22]. 5.3 TNF inhibitors As previously described, SARS-CoV" exact="infection" post="is associated with a downregulation of ACE2 expression coupled"/>
 <result pre="of TNF inhibitors may be effective in reducing both SARS-CoV2" exact="infection" post="and the consequent organ damage [100]. As a result,"/>
 <result pre="[100]. As a result, a study evaluating adalimumab in COVID-19" exact="infection" post="has recently been registered in the Chinese Clinical Trial"/>
 <result pre="ruxolitinib, and fedratinib, which have all been demonstrated to inhibit" exact="infection" post="of cells by Dengue virus, Ebola virus, and respiratory"/>
 <result pre="the plasma concentration obtained with the approved dosage for the" exact="treatment" post="of RA (2 to 4Â mg daily) [106]. Moreover,"/>
 <result pre="responses to prevent viral replication during the early phases of" exact="infection" post="[110]. The activation of transcription through JAK/STAT signaling pathway"/>
 <result pre="with a potential facilitating effect on the progression of SARS-CoV2" exact="infection" post="at the moment not yet better quantified. In conclusion,"/>
 <result pre="conclusion, evidence of the possible use of baricitinib in the" exact="treatment" post="of COVID-19 infection remains highly controversial and further studies"/>
 <result pre="the possible use of baricitinib in the treatment of COVID-19" exact="infection" post="remains highly controversial and further studies are warranted to"/>
 <result pre="are warranted to better clarify its potential role in the" exact="treatment" post="of more serious cases of viral pneumonia. 6 Conclusions"/>
 <result pre="factor. Thus, RA patients should be encouraged to continue their" exact="treatment" post="even during COVID-19 outbreak. In our opinion, this strategy"/>
 <result pre="interstitial pneumonia. Chloroquine and hydroxychloroquine are currently included in the" exact="treatment" post="protocol for the management of COVID-19 infections and might"/>
 <result pre="might be useful to prevent or mitigate the course of" exact="infection" post="in patients with RA taking them as csDMARDs. The"/>
 <result pre="studyLancet Respir Med202010.1016/s2213-2600(20)30079-5 8https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd(Accessed 17th March 2020) 9FavalliE.G.BiggioggeroM.MeroniP.L.Methotrexate for the" exact="treatment" post="of rheumatoid arthritis in the biologic era: still an"/>
 <result pre="ACE-Inhibitors and Angiotensin Receptor Blockers n.d. 17LiX.GengM.PengY.MengL.LuS.Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19J Pharm Analysis202010.1016/j.jpha.2020.03.001 18YildizH.NesteE.V.D.DefourJ.P.DanseE.YombiJ.C.Adult haemophagocytic lymphohistiocytosis: a reviewQjm"/>
 <result pre="to trace infectious triggers of autoimmunityAutoimmun Rev12201272674010.1016/j.autrev.2012.12.00523266520 25ArleevskayaM.I.ShafigullinaA.Z.FilinaY.V.LemerleJ.RenaudineauY.Associations between viral" exact="infection" post="history symptoms, granulocyte reactive oxygen species activity, and active"/>
 <result pre="of 86,039 seniors with rheumatoid arthritisArthritis Care Res65201335336110.1002/acr.21812 30DoranM.F.CrowsonC.S.PondG.R.Oâ€™FallonW.M.GabrielS.E.Frequency of" exact="infection" post="in patients with rheumatoid arthritis compared with controls: a"/>
 <result pre="with controls: a population-based studyArthritis Rheum4620022287229310.1002/art.1052412355475 31FranklinJ.LuntM.BunnD.SymmonsD.P.M.SilmanA.J.Risk and predictors of" exact="infection" post="leading to hospitalisation in a large primary-care-derived cohort of"/>
 <result pre="32AuK.ReedG.CurtisJ.R.KremerJ.M.GreenbergJ.D.StrandV.High disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis70201178579110.1136/ard.2010.12863721288960 33AccorttN.A.LesperanceT.LiuM.RebelloS.TrivediM.LiY.Impact of"/>
 <result pre="Dis70201178579110.1136/ard.2010.12863721288960 33AccorttN.A.LesperanceT.LiuM.RebelloS.TrivediM.LiY.Impact of sustained remission on the risk of serious" exact="infection" post="in patients with rheumatoid arthritisArthritis Care Res70201867968410.1002/acr.23426 34DougadosM.SoubrierM.AntunezA.BalintP.BalsaA.BuchM.H.Prevalence of"/>
 <result pre="42DixonW.G.SuissaS.HudsonM.The association between systemic glucocorticoid therapy and the risk of" exact="infection" post="in patients with rheumatoid arthritis: systematic review and meta-analysesArthritis"/>
 <result pre="respiratory syndromeAm J Resp Crit Care197201875776710.1164/rccm.201706-1172oc 45StockmanL.J.BellamyR.GarnerP.SARS: systematic review of" exact="treatment" post="effectsPLoS Med32006e34310.1371/journal.pmed.0030343 46MemishZ.A.PerlmanS.KerkhoveM.D.V.ZumlaA.Middle East respiratory syndromeLancet Lond Engl202010.1016/s0140-6736(19)33221-0 47NiY.-N.ChenG.SunJ.LiangB.-M.LiangZ.-A.The"/>
 <result pre="syndromeCochrane Database Syst Rev72019CD00447710.1002/14651858.cd004477.pub3 49RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet Lond Engl395202047347510.1016/s0140-6736(20)30317-2 50QiaoW.WangC.ChenB.ZhangF.LiuY.LuQ.Ibuprofen attenuates cardiac"/>
 <result pre="ratsCardiology13120159710610.1159/00037536225896805 51LacailleD.GuhD.P.AbrahamowiczM.AnisA.H.EsdaileJ.M.Use of nonbiologic disease-modifying antirheumatic drugs and risk of" exact="infection" post="in patients with rheumatoid arthritisArthritis Rheum5920081074108110.1002/art.2391318668604 52SmittenA.L.ChoiH.K.HochbergM.C.SuissaS.SimonT.A.TestaM.A.The risk of"/>
 <result pre="in patients with rheumatoid arthritisArthritis Rheum5920081074108110.1002/art.2391318668604 52SmittenA.L.ChoiH.K.HochbergM.C.SuissaS.SimonT.A.TestaM.A.The risk of hospitalized" exact="infection" post="in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection"/>
 <result pre="hospitalized infection in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
 <result pre="management of rheumatoid arthritisAnn Rheum Dis7620171101113610.1136/annrheumdis-2016-21070828298374 56FavalliE.G.DesiatiF.AtzeniF.Sarzi-PuttiniP.CaporaliR.PallaviciniF.B.Serious infections during anti-TNFÎ±" exact="treatment" post="in rheumatoid arthritis patientsAutoimmun Rev8200926627310.1016/j.autrev.2008.11.00219022409 57AtzeniF.Sarzi-PuttiniP.BotsiosC.CarlettoA.CiprianiP.FavalliE.G.Long-term anti-TNF therapy and"/>
 <result pre="adalimumab, etanercept and infliximab in the GISEA registryAutoimmun Rev12201222522910.1016/j.autrev.2012.06.00822796281 58RutherfordA.I.SubesingheS.HyrichK.L.GallowayJ.B.Serious" exact="infection" post="across biologic-treated patients with rheumatoid arthritis: results from the"/>
 <result pre="Biologics Register for Rheumatoid ArthritisAnn Rheum Dis77201890591010.1136/annrheumdis-2017-21282529592917 59SinghJ.A.CameronC.NoorbaloochiS.CullisT.TuckerM.ChristensenR.Risk of serious" exact="infection" post="in biological treatment of patients with rheumatoid arthritis: a"/>
 <result pre="Rheumatoid ArthritisAnn Rheum Dis77201890591010.1136/annrheumdis-2017-21282529592917 59SinghJ.A.CameronC.NoorbaloochiS.CullisT.TuckerM.ChristensenR.Risk of serious infection in biological" exact="treatment" post="of patients with rheumatoid arthritis: a systematic review and"/>
 <result pre="and cons of two different approaches to the disease modifying" exact="treatment" post="in rheumatoid arthritisAutoimmun Rev19201910242110.1016/j.autrev.2019.10242131733368 66FavalliE.G.Tofacitinibâ€™s infectious profile: concerns for"/>
 <result pre="arthritisAnn Rheum Dis7520161843184710.1136/annrheumdis-2016-20913127113415 70PawarA.DesaiR.J.GautamN.KimS.C.Risk of admission to hospital for serious" exact="infection" post="after initiating tofacitinib versus biologic DMARDs in patients with"/>
 <result pre="a multidatabase cohort studyLancet Rheumatol22020e84e9810.1016/s2665-9913(19)30137-7 71CaporaliR.ZavagliaD.Real-world experience with tofacitinib for" exact="treatment" post="of rheumatoid arthritisClin Exp Rheumatol373201948549530183607 72BiggioggeroM.BeccioliniA.CrottiC.AgapeE.FavalliE.G.Upadacitinib and filgotinib: the"/>
 <result pre="and filgotinib: the role of JAK1 selective inhibition in the" exact="treatment" post="of rheumatoid arthritisDrugs Context8201921259510.7573/dic.21259531692920 73JamillouxY.JammalT.E.VuittonL.Gerfaud-ValentinM.KereverS.SÃ¨veP.JAK inhibitors for the treatment"/>
 <result pre="the treatment of rheumatoid arthritisDrugs Context8201921259510.7573/dic.21259531692920 73JamillouxY.JammalT.E.VuittonL.Gerfaud-ValentinM.KereverS.SÃ¨veP.JAK inhibitors for the" exact="treatment" post="of autoimmune and inflammatory diseasesAutoimmun Rev18201910239010.1016/j.autrev.2019.10239031520803 74WinthropK.L.The emerging safety"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of Lopinavir/ritonavir for the treatment"/>
 <result pre="COVID-19 infection in Korea: the application of Lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RT-PCRJ Korean"/>
 <result pre="double-blind, placebo controlled trialLancet Infect Dis11201167768310.1016/s1473-3099(11)70065-221550310 87RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.Paradoxical effect of chloroquine" exact="treatment" post="in enhancing chikungunya virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent"/>
 <result pre="virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422x-2-6916115318 89DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects"/>
 <result pre="Registry. 2020. 92GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends202010.5582/bst.2020.01047 93YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="patients with features of macrophage activation syndromeCrit Care Med44201627528110.1097/ccm.000000000000140226584195 96XuX.HanM.LiT.SunW.WangD.FuB.Effective" exact="treatment" post="os severe COVID-19 patients with tocilizumabChinaXiv:202003000262020 97http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19(Accessed 17th March"/>
 <result pre="sunitinib and erlotinib for dengue treatmentAntiviral Res1552018677510.1016/j.antiviral.2018.05.00129753658 106RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet Lond Engl3952020e30e3110.1016/s0140-6736(20)30304-4 107FergusonF.M.GrayN.S.Kinase inhibitors:"/>
 <result pre="aheadNat Rev Drug Discov17201835337710.1038/nrd.2018.2129545548 108SanchezG.A.M.ReinhardtA.RamseyS.WittkowskiH.HashkesP.J.BerkunY.JAK1/2 inhibition with baricitinib in the" exact="treatment" post="of autoinflammatory interferonopathiesJ Clin Invest12820183041305210.1172/jci9881429649002 109VirtanenA.T.HaikarainenT.RaivolaJ.SilvennoinenO.Selective JAKinibs: prospects in"/>
 <result pre="protein 1 (NS1) disrupts interferon signalingPLoS One52010e1392710.1371/journal.pone.0013927 115ConigliaroP.TriggianeseP.MartinoE.D.FontiG.L.ChimentiM.S.SunziniF.Challenges in the" exact="treatment" post="of rheumatoid arthritisAutoimmun Rev18201970671310.1016/j.autrev.2019.05.00731059844 116FavalliE.G.RaimondoM.G.BeccioliniA.CrottiC.BiggioggeroM.CaporaliR.The management of first-line biologic"/>
</results>
